Mesoblast regains full rights to stem cell heart failure treatment

June 13 (Reuters) - Mesoblast Ltd on Monday said it

had regained full rights to its experimental stem cell therapy

for advanced chronic heart failure, which is currently in late

stage testing, from Teva Pharmaceutical Industries.

Read more